Phase 1 clinical study that will evaluate the safety, tolerability, and preliminary efficacy of INCAGN02390, an antagonist antibody specific for TIM-3. INCAGN02390 is an aglycosylated fully human IgG1κ monoclonal antibody that selectively binds to human TIM-3 and is being developed for the treatment of advanced malignancies

Type of Cancer

Phase

Division (Location)

Study ID

NCT#

Brief Description
Phase 1 clinical study that will evaluate the safety, tolerability, and preliminary efficacy of INCAGN02390, an antagonist antibody specific for TIM-3. INCAGN02390 is an aglycosylated fully human IgG1κ monoclonal antibody that selectively binds to human TIM-3 and is being developed for the treatment of advanced malignancies

To find out more about this clinical trial, or to schedule an appointment, call (201) 518-3587.